Inozyme Pharma Ownership 2024 | Who Owns Inozyme Pharma Now?
Institutional Ownership
11.07%
Insider Ownership
0.51%
Retail Ownership
88.42%
Institutional Holders
26.00
Inozyme Pharma Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 9.27% | 0.05% | 5,728,856 | 400,000 | 7.51% | 25,550,698 | Jun 30, 2024 |
| PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC | 7.28% | 15.41% | 4,494,851 | - | - | 20,047,035 | Jun 30, 2024 |
| SOFINNOVA INVESTMENTS, INC. | 6.93% | 0.99% | 4,280,308 | - | - | 19,090,174 | Jun 30, 2024 |
| EVENTIDE ASSET MANAGEMENT, LLC | 6.37% | 0.30% | 3,936,220 | 756,383 | 23.79% | 17,555,541 | Jun 30, 2024 |
| ROCK SPRINGS CAPITAL MANAGEMENT LP | 5.99% | 0.50% | 3,698,374 | 17,200 | 0.47% | 16,494,748 | Jun 30, 2024 |
| SAMLYN CAPITAL, LLC | 5.42% | 0.25% | 3,350,535 | 437,622 | 15.02% | 14,943,385 | Jun 30, 2024 |
| BLACKROCK INC. | 5.41% | 0.00% | 3,343,193 | 254,540 | 8.24% | 14,910,641 | Jun 30, 2024 |
| AFFINITY ASSET ADVISORS, LLC | 4.62% | 1.47% | 2,856,252 | 213,733 | 8.09% | 12,738,884 | Jun 30, 2024 |
| VANGUARD GROUP INC | 4.26% | 0.00% | 2,629,309 | 210,289 | 8.69% | 11,726,719 | Jun 30, 2024 |
| FMR LLC | 4.01% | 0.00% | 2,477,427 | 509,995 | 25.92% | 11,049,324 | Jun 30, 2024 |
| NEA MANAGEMENT COMPANY, LLC | 3.95% | 0.82% | 2,437,689 | - | - | 10,872,093 | Jun 30, 2024 |
| MILLENNIUM MANAGEMENT LLC | 2.89% | 0.00% | 1,787,947 | 1,084,341 | 154.11% | 7,974,244 | Jun 30, 2024 |
| SAMSARA BIOCAPITAL, LLC | 2.53% | 1.46% | 1,562,500 | - | - | 6,968,750 | Jun 30, 2024 |
| SPHERA FUNDS MANAGEMENT LTD. | 2.37% | 0.89% | 1,462,724 | 89,817 | 6.54% | 6,523,749 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.86% | 0.00% | 1,151,673 | 84,194 | 7.89% | 5,136,981 | Jun 30, 2024 |
| SATURN V CAPITAL MANAGEMENT LLC | 1.85% | 1.92% | 1,140,310 | 1,140,310 | 100.00% | 5,085,783 | Jun 30, 2024 |
| BLUE OWL CAPITAL HOLDINGS LP | 1.81% | 1.39% | 1,120,027 | -150,000 | -11.81% | 4,995,320 | Jun 30, 2024 |
| WOODLINE PARTNERS LP | 1.62% | 0.04% | 1,000,673 | 112,606 | 12.68% | 4,463,002 | Jun 30, 2024 |
| STATE STREET CORP | 1.62% | 0.00% | 1,000,034 | 119,395 | 13.56% | 4,460,152,000 | Jun 30, 2024 |
| KNOTT DAVID M JR | 0.91% | 1.00% | 564,549 | - | - | 2,518,000 | Jun 30, 2024 |
Inozyme Pharma's largest institutional shareholder is ADAGE CAPITAL PARTNERS GP, L.L.C., holding 9.27% of the company's total share outstanding, currently valued at $25.55M. The top 10 institutional shareholders own together 59.57% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC | 7.28% | 15.41% | 4,494,851 | - | - | 20,047,035 | Jun 30, 2024 |
| SATURN V CAPITAL MANAGEMENT LLC | 1.85% | 1.92% | 1,140,310 | 1,140,310 | 100.00% | 5,085,783 | Jun 30, 2024 |
| AFFINITY ASSET ADVISORS, LLC | 4.62% | 1.47% | 2,856,252 | 213,733 | 8.09% | 12,738,884 | Jun 30, 2024 |
| SAMSARA BIOCAPITAL, LLC | 2.53% | 1.46% | 1,562,500 | - | - | 6,968,750 | Jun 30, 2024 |
| BLUE OWL CAPITAL HOLDINGS LP | 1.81% | 1.39% | 1,120,027 | -150,000 | -11.81% | 4,995,320 | Jun 30, 2024 |
| KNOTT DAVID M JR | 0.91% | 1.00% | 564,549 | - | - | 2,518,000 | Jun 30, 2024 |
| SOFINNOVA INVESTMENTS, INC. | 6.93% | 0.99% | 4,280,308 | - | - | 19,090,174 | Jun 30, 2024 |
| SPHERA FUNDS MANAGEMENT LTD. | 2.37% | 0.89% | 1,462,724 | 89,817 | 6.54% | 6,523,749 | Jun 30, 2024 |
| NEA MANAGEMENT COMPANY, LLC | 3.95% | 0.82% | 2,437,689 | - | - | 10,872,093 | Jun 30, 2024 |
| ROCK SPRINGS CAPITAL MANAGEMENT LP | 5.99% | 0.50% | 3,698,374 | 17,200 | 0.47% | 16,494,748 | Jun 30, 2024 |
| EVENTIDE ASSET MANAGEMENT, LLC | 6.37% | 0.30% | 3,936,220 | 756,383 | 23.79% | 17,555,541 | Jun 30, 2024 |
| SAMLYN CAPITAL, LLC | 5.42% | 0.25% | 3,350,535 | 437,622 | 15.02% | 14,943,385 | Jun 30, 2024 |
| OVERBROOK MANAGEMENT CORP | 0.36% | 0.25% | 219,326 | - | - | 978,194 | Jun 30, 2024 |
| UBS OCONNOR LLC | 0.33% | 0.06% | 205,218 | 22,000 | 12.01% | 915,272 | Jun 30, 2024 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 9.27% | 0.05% | 5,728,856 | 400,000 | 7.51% | 25,550,698 | Jun 30, 2024 |
| VALUES FIRST ADVISORS, INC. | 0.03% | 0.05% | 17,067 | 17,067 | 100.00% | 76,119 | Jun 30, 2024 |
| WOODLINE PARTNERS LP | 1.62% | 0.04% | 1,000,673 | 112,606 | 12.68% | 4,463,002 | Jun 30, 2024 |
| CORTON CAPITAL INC. | 0.02% | 0.03% | 14,056 | 14,056 | 100.00% | 62,690 | Jun 30, 2024 |
| PALUMBO WEALTH MANAGEMENT LLC | 0.02% | 0.03% | 13,584 | 13,584 | 100.00% | 60,585 | Jun 30, 2024 |
| PALE FIRE CAPITAL SE | 0.06% | 0.02% | 38,901 | 38,901 | 100.00% | 173,498 | Jun 30, 2024 |
The largest Inozyme Pharma shareholder by % of total assets is PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC. The company owns 4.49M shares of Inozyme Pharma (INZY), representing 15.41% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| SATURN V CAPITAL MANAGEMENT LLC | 1.85% | 1.92% | 1,140,310 | 1,140,310 | 100.00% | 5,085,783 | Jun 30, 2024 |
| MILLENNIUM MANAGEMENT LLC | 2.89% | 0.00% | 1,787,947 | 1,084,341 | 154.11% | 7,974,244 | Jun 30, 2024 |
| EVENTIDE ASSET MANAGEMENT, LLC | 6.37% | 0.30% | 3,936,220 | 756,383 | 23.79% | 17,555,541 | Jun 30, 2024 |
| FMR LLC | 4.01% | 0.00% | 2,477,427 | 509,995 | 25.92% | 11,049,324 | Jun 30, 2024 |
| SAMLYN CAPITAL, LLC | 5.42% | 0.25% | 3,350,535 | 437,622 | 15.02% | 14,943,385 | Jun 30, 2024 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 9.27% | 0.05% | 5,728,856 | 400,000 | 7.51% | 25,550,698 | Jun 30, 2024 |
| BLACKROCK INC. | 5.41% | 0.00% | 3,343,193 | 254,540 | 8.24% | 14,910,641 | Jun 30, 2024 |
| AFFINITY ASSET ADVISORS, LLC | 4.62% | 1.47% | 2,856,252 | 213,733 | 8.09% | 12,738,884 | Jun 30, 2024 |
| VANGUARD GROUP INC | 4.26% | 0.00% | 2,629,309 | 210,289 | 8.69% | 11,726,719 | Jun 30, 2024 |
| DIMENSIONAL FUND ADVISORS LP | 0.62% | 0.00% | 380,064 | 205,417 | 117.62% | 1,695,249 | Jun 30, 2024 |
| STATE STREET CORP | 1.62% | 0.00% | 1,000,034 | 119,395 | 13.56% | 4,460,152,000 | Jun 30, 2024 |
| WOODLINE PARTNERS LP | 1.62% | 0.04% | 1,000,673 | 112,606 | 12.68% | 4,463,002 | Jun 30, 2024 |
| SPHERA FUNDS MANAGEMENT LTD. | 2.37% | 0.89% | 1,462,724 | 89,817 | 6.54% | 6,523,749 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.86% | 0.00% | 1,151,673 | 84,194 | 7.89% | 5,136,981 | Jun 30, 2024 |
| BANK OF AMERICA CORP /DE/ | 0.23% | 0.00% | 140,022 | 80,128 | 133.78% | 624,498 | Jun 30, 2024 |
| EXODUSPOINT CAPITAL MANAGEMENT, LP | 0.09% | 0.00% | 55,186 | 55,186 | 100.00% | 246,000 | Jun 30, 2024 |
| PALE FIRE CAPITAL SE | 0.06% | 0.02% | 38,901 | 38,901 | 100.00% | 173,498 | Jun 30, 2024 |
| COREBRIDGE FINANCIAL, INC. | 0.04% | 0.00% | 27,811 | 27,811 | 100.00% | 124,037 | Jun 30, 2024 |
| BANK OF NEW YORK MELLON CORP | 0.31% | 0.00% | 190,896 | 26,464 | 16.09% | 851,397 | Jun 30, 2024 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 0.04% | 0.00% | 24,405 | 24,405 | 100.00% | 108,846 | Jun 30, 2024 |
As of Jun 30 2024, Inozyme Pharma's largest institutional buyer is SATURN V CAPITAL MANAGEMENT LLC. The company purchased 1.14M stocks of INZY, valued at $5.09M.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| KENNEDY CAPITAL MANAGEMENT LLC | - | - | - | -437,657 | -100.00% | - | Jun 30, 2024 |
| LAURION CAPITAL MANAGEMENT LP | 0.20% | 0.01% | 126,541 | -275,656 | -68.54% | 564,373 | Jun 30, 2024 |
| EXOME ASSET MANAGEMENT LLC | - | - | - | -273,413 | -100.00% | - | Jun 30, 2024 |
| PARKMAN HEALTHCARE PARTNERS LLC | - | - | - | -222,943 | -100.00% | - | Jun 30, 2024 |
| BLUE OWL CAPITAL HOLDINGS LP | 1.81% | 1.39% | 1,120,027 | -150,000 | -11.81% | 4,995,320 | Jun 30, 2024 |
| SUPERSTRING CAPITAL MANAGEMENT LP | - | - | - | -112,739 | -100.00% | - | Jun 30, 2024 |
| GSA CAPITAL PARTNERS LLP | 0.07% | 0.01% | 40,931 | -90,167 | -68.78% | 183,000 | Jun 30, 2024 |
| SCHONFELD STRATEGIC ADVISORS LLC | - | - | - | -74,800 | -100.00% | - | Jun 30, 2024 |
| PRELUDE CAPITAL MANAGEMENT, LLC | - | - | - | -62,445 | -100.00% | - | Jun 30, 2024 |
| GOLDMAN SACHS GROUP INC | 0.59% | 0.00% | 361,868 | -48,055 | -11.72% | 1,613,931 | Jun 30, 2024 |
| MORGAN STANLEY | 0.13% | - | 78,898 | -45,348 | -36.50% | 351,885 | Jun 30, 2024 |
| JPMORGAN CHASE & CO | 0.04% | - | 22,077 | -39,500 | -64.15% | 98,464 | Jun 30, 2024 |
| CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | - | - | - | -34,832 | -100.00% | - | Jun 30, 2024 |
| UBS GROUP AG | 0.03% | - | 15,773 | -32,187 | -67.11% | 70,348 | Jun 30, 2024 |
| BALYASNY ASSET MANAGEMENT L.P. | - | - | - | -31,380 | -100.00% | - | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | - | - | - | -29,893 | -100.00% | - | Jun 30, 2024 |
| AMERICAN INTERNATIONAL GROUP, INC. | - | - | - | -23,528 | -100.00% | - | Jun 30, 2024 |
| DENALI ADVISORS LLC | - | - | - | -22,000 | -100.00% | - | Jun 30, 2024 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | - | - | - | -17,800 | -100.00% | - | Jun 30, 2024 |
| LIDO ADVISORS, LLC | - | - | - | -17,108 | -100.00% | - | Jun 30, 2024 |
As of Jun 30 2024, Inozyme Pharma's biggest institutional seller is KENNEDY CAPITAL MANAGEMENT LLC. The company sold -0.44M shares of INZY, valued at -.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| SATURN V CAPITAL MANAGEMENT LLC | 1.85% | 1.92% | 1,140,310 | 1,140,310 | 100.00% | 5,085,783 | Jun 30, 2024 |
| EXODUSPOINT CAPITAL MANAGEMENT, LP | 0.09% | 0.00% | 55,186 | 55,186 | 100.00% | 246,000 | Jun 30, 2024 |
| PALE FIRE CAPITAL SE | 0.06% | 0.02% | 38,901 | 38,901 | 100.00% | 173,498 | Jun 30, 2024 |
| COREBRIDGE FINANCIAL, INC. | 0.04% | 0.00% | 27,811 | 27,811 | 100.00% | 124,037 | Jun 30, 2024 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 0.04% | 0.00% | 24,405 | 24,405 | 100.00% | 108,846 | Jun 30, 2024 |
| CUBIST SYSTEMATIC STRATEGIES, LLC | 0.03% | 0.00% | 18,891 | 18,891 | 100.00% | 84,254 | Jun 30, 2024 |
| MEEDER ASSET MANAGEMENT INC | 0.02% | 0.00% | 15,210 | 15,210 | 100.00% | 67,837 | Jun 30, 2024 |
| CORTON CAPITAL INC. | 0.02% | 0.03% | 14,056 | 14,056 | 100.00% | 62,690 | Jun 30, 2024 |
| PALUMBO WEALTH MANAGEMENT LLC | 0.02% | 0.03% | 13,584 | 13,584 | 100.00% | 60,585 | Jun 30, 2024 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 0.02% | 0.00% | 11,591 | 11,591 | 100.00% | 51,696 | Jun 30, 2024 |
| PROSPERA FINANCIAL SERVICES INC | 0.02% | 0.00% | 11,155 | 11,155 | 100.00% | 49,751 | Jun 30, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | 0.02% | 0.00% | 10,765 | 10,765 | 100.00% | 48,012 | Jun 30, 2024 |
| REDWOOD WEALTH MANAGEMENT GROUP, LLC | 0.01% | 0.02% | 4,500 | 4,500 | 100.00% | 20,070 | Jun 30, 2024 |
| SRS CAPITAL ADVISORS, INC. | 0.00% | 0.00% | 475 | 475 | 100.00% | 2,119 | Jun 30, 2024 |
| RUSSELL INVESTMENTS GROUP, LTD. | 0.00% | - | 433 | 433 | 100.00% | 1,931 | Jun 30, 2024 |
| ALLSPRING GLOBAL INVESTMENTS HOLDINGS, LLC | 0.00% | - | 66 | 66 | 100.00% | 294 | Jun 30, 2024 |
| PNC FINANCIAL SERVICES GROUP, INC. | 0.00% | - | 35 | 35 | 100.00% | 156 | Jun 30, 2024 |
| ROTHSCHILD INVESTMENT LLC | - | - | 25 | 25 | 100.00% | 112 | Jun 30, 2024 |
Inozyme Pharma's largest new institutional shareholder by number of shares is SATURN V CAPITAL MANAGEMENT LLC, purchased 1.14M shares, valued at $5.09M, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| KENNEDY CAPITAL MANAGEMENT LLC | - | - | - | -437,657 | -100.00% | - | Jun 30, 2024 |
| EXOME ASSET MANAGEMENT LLC | - | - | - | -273,413 | -100.00% | - | Jun 30, 2024 |
| PARKMAN HEALTHCARE PARTNERS LLC | - | - | - | -222,943 | -100.00% | - | Jun 30, 2024 |
| SUPERSTRING CAPITAL MANAGEMENT LP | - | - | - | -112,739 | -100.00% | - | Jun 30, 2024 |
| SCHONFELD STRATEGIC ADVISORS LLC | - | - | - | -74,800 | -100.00% | - | Jun 30, 2024 |
| PRELUDE CAPITAL MANAGEMENT, LLC | - | - | - | -62,445 | -100.00% | - | Jun 30, 2024 |
| CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | - | - | - | -34,832 | -100.00% | - | Jun 30, 2024 |
| BALYASNY ASSET MANAGEMENT L.P. | - | - | - | -31,380 | -100.00% | - | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | - | - | - | -29,893 | -100.00% | - | Jun 30, 2024 |
| AMERICAN INTERNATIONAL GROUP, INC. | - | - | - | -23,528 | -100.00% | - | Jun 30, 2024 |
| DENALI ADVISORS LLC | - | - | - | -22,000 | -100.00% | - | Jun 30, 2024 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | - | - | - | -17,800 | -100.00% | - | Jun 30, 2024 |
| LIDO ADVISORS, LLC | - | - | - | -17,108 | -100.00% | - | Jun 30, 2024 |
| SG AMERICAS SECURITIES, LLC | - | - | - | -13,926 | -100.00% | - | Jun 30, 2024 |
| METROPOLITAN LIFE INSURANCE CO/NY | - | - | - | -2,728 | -100.00% | - | Jun 30, 2024 |
| ENTRYPOINT CAPITAL, LLC | - | - | - | -1,460 | -100.00% | - | Jun 30, 2024 |
| SIGNATUREFD, LLC | - | - | - | -113 | -100.00% | - | Jun 30, 2024 |
| ICA GROUP WEALTH MANAGEMENT, LLC | - | - | - | -85 | -100.00% | - | Jun 30, 2024 |
| NELSON, VAN DENBURG & CAMPBELL WEALTH MANAGEMENT GROUP, LLC | - | - | - | -9 | -100.00% | - | Jun 30, 2024 |
Inozyme Pharma's largest sold out institutional shareholder by shares sold is KENNEDY CAPITAL MANAGEMENT LLC, sold -0.44M shares, valued at -, as of undefined.
Inozyme Pharma Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| VANGUARD VALLEY FORGE FUNDS | 0.06% | 29,430 | - | - | Mar 31, 2024 |
| FIDELITY SELECT PORTFOLIOS | 0.02% | 1,515,687 | -751,500 | -33.15% | Feb 29, 2024 |
| TIAA SEPARATE ACCOUNT VA 1 | 0.02% | 4,356 | - | - | Mar 31, 2024 |
| BlackRock Advantage SMID Cap Fund, Inc. | 0.02% | 3,382 | - | - | Mar 28, 2024 |
| DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.01% | 7,206 | - | - | Mar 31, 2024 |
| QUANTITATIVE MASTER SERIES LLC | 0.01% | 56,742 | - | - | Mar 31, 2024 |
| BRIDGEWAY FUNDS INC | 0.01% | 14,400 | -34,000 | -70.25% | Mar 28, 2024 |
| VANGUARD INDEX FUNDS | 0.00% | 2,034,300 | -676,904 | -24.97% | Mar 31, 2024 |
| ALPS ETF Trust | 0.00% | 45,705 | 45,705 | - | Feb 29, 2024 |
| SCHWAB CAPITAL TRUST | 0.00% | 121,650 | 27,655 | 29.42% | Jan 31, 2024 |
| JPMORGAN INSURANCE TRUST | 0.00% | 37,800 | - | - | Mar 31, 2023 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 439,472 | 37,760 | 9.40% | Feb 29, 2024 |
| GOLDMAN SACHS VARIABLE INSURANCE TRUST | 0.00% | 8,057 | 4,208 | 109.33% | Mar 31, 2024 |
| Calvert Variable Products, Inc. | 0.00% | 4,805 | - | - | Mar 31, 2024 |
| Legg Mason ETF Investment Trust | 0.00% | 2,810 | - | - | Mar 31, 2024 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 37,862 | 15,031 | 65.84% | Mar 31, 2024 |
| Voya INVESTORS TRUST | 0.00% | 61,800 | - | - | Mar 31, 2024 |
| AdvisorShares Trust | 0.00% | 3,445 | - | - | Mar 28, 2024 |
| MUTUAL FUND SERIES TRUST | 0.00% | 3,179,837 | - | - | Mar 31, 2024 |
| Voya VARIABLE PORTFOLIOS INC | 0.00% | 15,914 | -4,166 | -20.75% | Mar 31, 2024 |
| STATE STREET VARIABLE INSURANCE SERIES FUNDS INC | 0.00% | 2,261 | 271 | 13.62% | Mar 31, 2024 |
| AMERICAN CENTURY ETF TRUST | 0.00% | 33,810 | 11,886 | 54.21% | Feb 29, 2024 |
| NORTHERN FUNDS | 0.00% | 36,695 | -700 | -1.87% | Mar 28, 2024 |
| STATE STREET INSTITUTIONAL INVESTMENT TRUST | 0.00% | 16,200 | -5,700 | -26.03% | Mar 31, 2024 |
| NATIONWIDE MUTUAL FUNDS | 0.00% | 30,099 | 24,407 | 428.79% | Jan 31, 2024 |
| TIAA-CREF LIFE FUNDS | 0.00% | 608 | - | - | Mar 31, 2024 |
| VARIABLE INSURANCE PRODUCTS FUND II | 0.00% | 2,676 | 353 | 15.20% | Mar 31, 2024 |
| RUSSELL INVESTMENT CO | 0.00% | 64,806 | - | - | Jan 31, 2024 |
| NATIONWIDE VARIABLE INSURANCE TRUST | 0.00% | 24,038 | 10,662 | 79.71% | Mar 31, 2024 |
| VANGUARD WELLINGTON FUND | 0.00% | 53,040 | - | - | Feb 29, 2024 |
| T. Rowe Price Index Trust, Inc. | 0.00% | 2,916 | - | - | Mar 31, 2024 |
| SunAmerica Specialty Series | 0.00% | 67 | - | - | Apr 30, 2021 |
| iSHARES TRUST | 0.00% | 1,741,319 | -40,993 | -2.30% | Mar 31, 2024 |
| VANGUARD SCOTTSDALE FUNDS | 0.00% | 210,337 | 79,984 | 61.36% | Feb 29, 2024 |
| RUSSELL INVESTMENT FUNDS | 0.00% | 10,935 | - | - | Mar 31, 2024 |
| EQ ADVISORS TRUST | 0.00% | 98,595 | -312 | -0.32% | Mar 31, 2024 |
| RYDEX SERIES FUNDS | 0.00% | 309 | - | - | Dec 31, 2023 |
| Dimensional ETF Trust | 0.00% | 30,055 | 5,199 | 20.92% | Jan 31, 2024 |
| VALIC Co I | 0.00% | 18,321 | 5,279 | 40.48% | Feb 29, 2024 |
| SCHWAB STRATEGIC TRUST | 0.00% | 34,074 | - | - | Feb 29, 2024 |
| MAINSTAY VP FUNDS TRUST | 0.00% | 5,621 | 5,621 | - | Mar 31, 2024 |
| PENN SERIES FUNDS INC | 0.00% | 1,300 | - | - | Mar 28, 2024 |
| TIAA-CREF FUNDS | 0.00% | 135,144 | 19,277 | 16.64% | Jan 31, 2024 |
| RYDEX DYNAMIC FUNDS | 0.00% | 153 | - | - | Dec 31, 2023 |
| DFA INVESTMENT DIMENSIONS GROUP INC | 0.00% | 34,895 | 25,045 | 254.26% | Jan 31, 2024 |
| ProFunds | 0.00% | 371 | -30 | -7.48% | Mar 31, 2024 |
| PROSHARES TRUST | 0.00% | 6,996 | 2,626 | 60.09% | Feb 29, 2024 |
| MORGAN STANLEY PATHWAY FUNDS | 0.00% | 2,635 | 1,530 | 138.46% | Feb 29, 2024 |
| USAA MUTUAL FUNDS TRUST | 0.00% | 5,675 | 791 | 16.20% | Jan 31, 2024 |
| PGIM ETF TRUST | 0.00% | 1,442 | - | - | Feb 29, 2024 |
| RYDEX VARIABLE TRUST | 0.00% | 20 | - | - | Dec 31, 2023 |
| COLLEGE RETIREMENT EQUITIES FUND | 0.00% | 16,918 | - | - | Mar 31, 2024 |
| SUNAMERICA SERIES TRUST | 0.00% | 5,409 | 1,559 | 40.49% | Jan 31, 2024 |
| Guggenheim Active Allocation Fund | 0.00% | 85 | - | - | Feb 29, 2024 |
| Brinker Capital Destinations Trust | 0.00% | 828 | 828 | - | Feb 29, 2024 |
| LINCOLN VARIABLE INSURANCE PRODUCTS TRUST | 0.00% | 28,500 | - | - | Mar 31, 2024 |
| Brighthouse Funds Trust II | 0.00% | 9,560 | -7,301 | -43.30% | Mar 31, 2024 |
| MASTER INVESTMENT PORTFOLIO | 0.00% | 892 | - | - | Mar 31, 2024 |
| Blackstone Alternative Investment Funds | 0.00% | 1,200 | -400 | -25.00% | Mar 31, 2024 |
| GOLDMAN SACHS TRUST | 0.00% | 33,685 | 25,648 | 319.12% | Jan 31, 2024 |
| FIDELITY SALEM STREET TRUST | 0.00% | 35,385 | -952 | -2.62% | Mar 31, 2024 |
| JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 18,473 | -5,764 | -23.78% | Mar 31, 2024 |
| ETF Series Solutions | 0.00% | 115 | - | - | Jan 31, 2024 |
| PACIFIC SELECT FUND | 0.00% | 19,831 | -395 | -1.95% | Mar 31, 2024 |
| Bridge Builder Trust | 0.00% | 19,705 | - | - | Mar 31, 2024 |
| Invesco Exchange-Traded Fund Trust II | 0.00% | 708 | - | - | Jan 31, 2024 |
| BlackRock Variable Series Funds, Inc. | 0.00% | 6,484 | - | - | Mar 31, 2024 |
| MASSMUTUAL SELECT FUNDS | 0.00% | 1,299 | - | - | Dec 31, 2023 |
| Advisors' Inner Circle Fund III | 0.00% | 133 | 133 | - | Jan 31, 2024 |
| PRINCIPAL FUNDS, INC. | 0.00% | 6,004 | 1,024 | 20.56% | Jan 31, 2024 |
| BLACKROCK FUNDS | 0.00% | 3,298 | - | - | Jan 31, 2024 |
| SEI INSTITUTIONAL INVESTMENTS TRUST | 0.00% | 3,069 | - | - | Feb 29, 2024 |
| John Hancock Funds II | 0.00% | 2,067 | - | - | Feb 29, 2024 |
Inozyme Pharma's largest mutual fund holder by % of total assets is "VANGUARD VALLEY FORGE FUNDS", owning 29.43K shares, compromising 0.06% of its total assets.
Inozyme Pharma Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 24 | 26 | -71.43% |
| 31 Mar, 24 | 91 | 9.64% |
| 31 Dec, 23 | 83 | 2.47% |
| 30 Sep, 23 | 81 | 6.58% |
| 30 Jun, 23 | 76 | 46.15% |
| 31 Mar, 23 | 52 | 44.44% |
| 31 Dec, 22 | 36 | - |
| 30 Sep, 22 | 36 | -16.28% |
| 30 Jun, 22 | 43 | -10.42% |
| 31 Mar, 22 | 48 | -4.00% |
| 31 Dec, 21 | 50 | -1.96% |
| 30 Sep, 21 | 51 | 4.08% |
| 30 Jun, 21 | 49 | -9.26% |
| 31 Mar, 21 | 54 | - |
| 31 Dec, 20 | 54 | 5.88% |
| 30 Sep, 20 | 51 | - |
As of 30 Jun 24, 26 institutions are holding Inozyme Pharma's shares, representing a decrease of -71.43% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 24 | 6,837,416 | -86.29% |
| 31 Mar, 24 | 49,874,140 | -0.33% |
| 31 Dec, 23 | 50,036,907 | 2.76% |
| 30 Sep, 23 | 48,693,887 | 42.67% |
| 30 Jun, 23 | 34,130,027 | 6.80% |
| 31 Mar, 23 | 31,956,218 | 9.88% |
| 31 Dec, 22 | 29,083,364 | -5.69% |
| 30 Sep, 22 | 30,838,268 | -2.25% |
| 30 Jun, 22 | 31,549,652 | 81.24% |
| 31 Mar, 22 | 17,407,936 | 0.45% |
| 31 Dec, 21 | 17,329,750 | -0.52% |
| 30 Sep, 21 | 17,419,787 | -11.65% |
| 30 Jun, 21 | 19,717,110 | 3.24% |
| 31 Mar, 21 | 19,098,677 | 4.02% |
| 31 Dec, 20 | 18,361,438 | 12.68% |
| 30 Sep, 20 | 16,294,780 | - |
Inozyme Pharma (INZY) has 6.84M shares outstanding as of 30 Jun 24, down -86.29% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 24 | 11.07% | 0.12% |
| 31 Mar, 24 | 96.21% | 1.24% |
| 31 Dec, 23 | 88.16% | 0.75% |
| 30 Sep, 23 | 108.55% | 1.78% |
| 30 Jun, 23 | 78.06% | 1.46% |
| 31 Mar, 23 | 73.09% | 1.23% |
| 31 Dec, 22 | 77.02% | 1.54% |
| 30 Sep, 22 | 70.64% | 1.12% |
| 30 Jun, 22 | 79.46% | 1.47% |
| 31 Mar, 22 | 73.49% | 1.36% |
| 31 Dec, 21 | 73.56% | 1.36% |
| 30 Sep, 21 | 73.68% | 1.05% |
| 30 Jun, 21 | 83.94% | 1.26% |
| 31 Mar, 21 | 81.52% | 0.79% |
| 31 Dec, 20 | 101.44% | 1.25% |
| 30 Sep, 20 | 90.02% | - |
As of 30 Jun 24, Inozyme Pharma is held by 11.07% institutional shareholders, representing a 0.12% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 18 | -56.10% |
| 31 Mar, 24 | 41 | -22.64% |
| 31 Dec, 23 | 53 | 20.45% |
| 30 Sep, 23 | 44 | -22.81% |
| 30 Jun, 23 | 57 | 58.33% |
| 31 Mar, 23 | 36 | 125.00% |
| 31 Dec, 22 | 16 | 23.08% |
| 30 Sep, 22 | 13 | -55.17% |
| 30 Jun, 22 | 29 | 45.00% |
| 31 Mar, 22 | 20 | -16.67% |
| 31 Dec, 21 | 24 | - |
| 30 Sep, 21 | 24 | - |
| 30 Jun, 21 | 24 | -7.69% |
| 31 Mar, 21 | 26 | -16.13% |
| 31 Dec, 20 | 31 | -39.22% |
| 30 Sep, 20 | 51 | - |
18 institutional shareholders have increased their position in INZY stock as of 30 Jun 24 compared to 41 in the previous quarter (a -56.10% decrease).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 2 | -93.55% |
| 31 Mar, 24 | 31 | 106.67% |
| 31 Dec, 23 | 15 | -25.00% |
| 30 Sep, 23 | 20 | 81.82% |
| 30 Jun, 23 | 11 | 120.00% |
| 31 Mar, 23 | 5 | -54.55% |
| 31 Dec, 22 | 11 | -21.43% |
| 30 Sep, 22 | 14 | 16.67% |
| 30 Jun, 22 | 12 | -29.41% |
| 31 Mar, 22 | 17 | 21.43% |
| 31 Dec, 21 | 14 | - |
| 30 Sep, 21 | 14 | 7.69% |
| 30 Jun, 21 | 13 | 18.18% |
| 31 Mar, 21 | 11 | 57.14% |
| 31 Dec, 20 | 7 | - |
| 30 Sep, 20 | - | - |
2 institutional shareholders have reduced their position in INZY stock as of 30 Jun 24 compared to 31 in the previous quarter (a -93.55% decrease).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 24 | 26 | -71.43% | 6,837,416 | -86.29% | 11.07% | 0.12% | 18 | -56.10% | 2 | -93.55% |
| 31 Mar, 24 | 91 | 9.64% | 49,874,140 | -0.33% | 96.21% | 1.24% | 41 | -22.64% | 31 | 106.67% |
| 31 Dec, 23 | 83 | 2.47% | 50,036,907 | 2.76% | 88.16% | 0.75% | 53 | 20.45% | 15 | -25.00% |
| 30 Sep, 23 | 81 | 6.58% | 48,693,887 | 42.67% | 108.55% | 1.78% | 44 | -22.81% | 20 | 81.82% |
| 30 Jun, 23 | 76 | 46.15% | 34,130,027 | 6.80% | 78.06% | 1.46% | 57 | 58.33% | 11 | 120.00% |
| 31 Mar, 23 | 52 | 44.44% | 31,956,218 | 9.88% | 73.09% | 1.23% | 36 | 125.00% | 5 | -54.55% |
| 31 Dec, 22 | 36 | - | 29,083,364 | -5.69% | 77.02% | 1.54% | 16 | 23.08% | 11 | -21.43% |
| 30 Sep, 22 | 36 | -16.28% | 30,838,268 | -2.25% | 70.64% | 1.12% | 13 | -55.17% | 14 | 16.67% |
| 30 Jun, 22 | 43 | -10.42% | 31,549,652 | 81.24% | 79.46% | 1.47% | 29 | 45.00% | 12 | -29.41% |
| 31 Mar, 22 | 48 | -4.00% | 17,407,936 | 0.45% | 73.49% | 1.36% | 20 | -16.67% | 17 | 21.43% |
| 31 Dec, 21 | 50 | -1.96% | 17,329,750 | -0.52% | 73.56% | 1.36% | 24 | - | 14 | - |
| 30 Sep, 21 | 51 | 4.08% | 17,419,787 | -11.65% | 73.68% | 1.05% | 24 | - | 14 | 7.69% |
| 30 Jun, 21 | 49 | -9.26% | 19,717,110 | 3.24% | 83.94% | 1.26% | 24 | -7.69% | 13 | 18.18% |
| 31 Mar, 21 | 54 | - | 19,098,677 | 4.02% | 81.52% | 0.79% | 26 | -16.13% | 11 | 57.14% |
| 31 Dec, 20 | 54 | 5.88% | 18,361,438 | 12.68% | 101.44% | 1.25% | 31 | -39.22% | 7 | - |
| 30 Sep, 20 | 51 | - | 16,294,780 | - | 90.02% | - | 51 | - | - | - |
Inozyme Pharma Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
Insider Sells
All Insider Owners Trades
The last insider sell of Inozyme Pharma's stock was made by Treco Douglas A on Apr 03 2024, selling 25,000 shares at - per share (valued at -). The last insider buy of INZY was made by Pivotal bioVenture Partners Fund I, L.P. on Aug 03 2023, buying 119,048 shares at $4.80 per share (worth $571.43K).
Inozyme Pharma Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q2 2024 | 8 | 2 | 400.00% |
| Q1 2024 | 4 | - | - |
| Q3 2023 | 5 | - | - |
| Q2 2023 | 13 | - | - |
| Q1 2023 | 6 | - | - |
| Q4 2022 | 1 | - | - |
| Q3 2022 | 2 | - | - |
| Q2 2022 | 20 | - | - |
| Q1 2022 | 3 | - | - |
| Q2 2021 | 9 | 2 | 450.00% |
| Q1 2021 | 12 | 1 | 1200.00% |
| Q3 2020 | 53 | 54 | 98.15% |
8 total buy trades, and 2 total sell trades (buy/sell ratio of 4.00%) were made by Inozyme Pharma's insiders, as of Q2 2024.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q2 2024 | - | 1 | - |
| Q1 2024 | - | - | - |
| Q3 2023 | 4 | - | - |
| Q2 2023 | 2 | - | - |
| Q1 2023 | 3 | - | - |
| Q4 2022 | 1 | - | - |
| Q3 2022 | - | - | - |
| Q2 2022 | 8 | - | - |
| Q1 2022 | - | - | - |
| Q2 2021 | - | 1 | - |
| Q1 2021 | - | 1 | - |
| Q3 2020 | 16 | - | - |
As of Q2 2024, Insider owners conducted 0 open market buy trades and 1 open market sell trades of Inozyme Pharma's stocks.
Inozyme Pharma Peer Ownership
INZY Ownership FAQ
Who Owns Inozyme Pharma?
Inozyme Pharma is owned by institutional shareholders (11.07%), insiders (0.51%), and public (88.42%). The largest institutional shareholder of Inozyme Pharma is ADAGE CAPITAL PARTNERS GP, L.L.C. (9.27% of total shares) and the top mutual fund owner is VANGUARD VALLEY FORGE FUNDS (0.06% of total shares).
Who are the major institutional shareholders of Inozyme Pharma?
Inozyme Pharma's major institutional shareholders are ADAGE CAPITAL PARTNERS GP, L.L.C., PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC, SOFINNOVA INVESTMENTS, INC., EVENTIDE ASSET MANAGEMENT, LLC, and ROCK SPRINGS CAPITAL MANAGEMENT LP. The top five shareholders own together 35.84% of the company's share outstanding.
How many Inozyme Pharma shareholders are there?
As of Jun 2024, there are 26 institutional shareholders of Inozyme Pharma.
What percentage of Inozyme Pharma is owned by ADAGE CAPITAL PARTNERS GP, L.L.C?
ADAGE CAPITAL PARTNERS GP, L.L.C owns 5.73M shares of Inozyme Pharma, representing 9.27% of the company's total shares outstanding, valued at $25.55M (as of Jun 2024).
What percentage of Inozyme Pharma is owned by PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC?
As of Jun 2024, PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC holds 4.49M shares of Inozyme Pharma (INZY), compromising 7.28% of the company, valued at $20.05M.
What percentage of Inozyme Pharma is owned by SOFINNOVA INVESTMENTS, INC?
SOFINNOVA INVESTMENTS, INC is the third largest holder of Inozyme Pharma. The company owns 4.28M of the company's shares outstanding (worth $19.09M).